PSYCHOPHARMACOLOGIC
DRUGS ADVISORY COMMITTEE Hilton Hotel, The Ballrooms,
|
|
FDA Overview |
Paul Andreason, M.D. Deputy Director, Division
of Psychiatry Products, CDER, FDA |
FDA Presentation |
Robert Levin, M.D. Medical Officer Division of Psychiatry Products, CDER, FDA |
Sponsor
Presentation |
|
Introduction |
Douglas Hay, Ph.D. Senior Vice President Global Regulatory Affairs Shire Pharmaceuticals |
ADHD: Current Treatment |
Marc Lerner, M.D. Clinical Professor of Pediatrics |
Clinical Efficacy of MTS in
Children with ADHD |
Liza Squires,
M.D. Senior Director Global Clinical Medicine Shire Pharmaceuticals |
MTS Safety Evaluations |
Raymond Pratt, M.D. Shire Pharmaceuticals |
MTS: Clinical Perspective |
Sharon
Wigal, Ph.D. Associate Clinical Professor of Pediatrics |
Benefit/Risk Summary |
Raymond Pratt, M.D. Shire Pharmaceuticals |
Questions to the Committee |
|